These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20428379)

  • 41. [A study of immunological efficacy of the oral chemical cholera vaccine on experimental animals].
    Dzhaparidze MN; Egorova VD; Karaeva LT; Sumarokov AA; Gor'kova Av
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Nov; (11):115-9. PubMed ID: 1007720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholera, 2013.
    Wkly Epidemiol Rec; 2014 Aug; 89(31):345-55. PubMed ID: 25089321
    [No Abstract]   [Full Text] [Related]  

  • 43. Home Administration of CVD 103-HgR: A Live Attenuated Oral Cholera Vaccine.
    Duffin RP; Delbuono M; Chew L; Johnstone J; Niedan V; Schwarz P; Shabram P; Patel AA
    Am J Trop Med Hyg; 2021 Mar; 104(4):1232-1240. PubMed ID: 33646977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Not one but four possible oral vaccines for cholera under study.
    Henahan J
    JAMA; 1982 Oct; 248(16):1937-8. PubMed ID: 7120612
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.
    Levine MM
    BMC Biol; 2010 Oct; 8():129. PubMed ID: 20920375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Determination of Vibrio antibody titers during anti-cholera vaccination].
    Dirimci OT; Cinar V
    Turk Hij Tecr Biyol Derg (1961); 1973; 33(2-3):118-28. PubMed ID: 4807572
    [No Abstract]   [Full Text] [Related]  

  • 48. Experience with registered mucosal vaccines.
    Dietrich G; Griot-Wenk M; Metcalfe IC; Lang AB; Viret JF
    Vaccine; 2003 Jan; 21(7-8):678-83. PubMed ID: 12531339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of cholera.
    Preston NW
    Lancet; 2004 Mar; 363(9412):898. PubMed ID: 15031046
    [No Abstract]   [Full Text] [Related]  

  • 50. [O-antigen of Vibrio cholerae, serovar Ogawa, Recommended for the production of oral cholera bivalent vaccine].
    Dzhaparidze MN; Karaeva LT; Sumarokov AA; Marchuk LM; Nikitina GP
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):75-81. PubMed ID: 7324656
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunogenicity and protective role of three formulations of oral cholera vaccine.
    Kalambaheti T; Chaisri U; Srimanote P; Pongponratn E; Chaicumpa W
    Vaccine; 1998; 16(2-3):201-7. PubMed ID: 9607031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decades of cholera in Odisha, India (1993-2015): lessons learned and the ways forward.
    Khuntia HK; Ramamurthy T; Bal M; Pati S; Ranjit M
    Epidemiol Infect; 2021 Jun; 149():e148. PubMed ID: 34096499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attenuation of virulence by P and V plasmids in Vibrio cholerae: strains suitable for oral immunization.
    Sinha VB; Srivastava BS
    Bull World Health Organ; 1979; 57(4):643-7. PubMed ID: 316741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers.
    Levine MM; Kaper JB; Herrington D; Losonsky G; Tacket C; Tall B
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):401-15. PubMed ID: 3217822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
    Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G
    Infect Immun; 1989 Nov; 57(11):3261-4. PubMed ID: 2807523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

  • 57. Simultaneous vaccination against cholera and yellow fever.
    Felsenfeld O; Wolf RH; Gyr K; Grant LS; Dutta NK
    Lancet; 1973 Mar; 1(7801):457-8. PubMed ID: 4120368
    [No Abstract]   [Full Text] [Related]  

  • 58. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
    Jackson SS; Chen WH
    Future Microbiol; 2015; 10(8):1271-81. PubMed ID: 26228388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral cholera vaccine development and use in Vietnam.
    Anh DD; Lopez AL; Tran HT; Cuong NV; Thiem VD; Ali M; Deen JL; von Seidlein L; Sack DA
    PLoS Med; 2014 Sep; 11(9):e1001712. PubMed ID: 25180511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
    Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
    Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.